期刊
KIDNEY INTERNATIONAL
卷 98, 期 2, 页码 294-309出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.04.020
关键词
acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement therapy; risk stratification
资金
- KDIGO
- Akebia Therapeutics
- Angion
- AMPharma
- AstraZeneca
- Astute Medical
- Atox Bio
- Baxter
- bioMerieux
- BioPorto
- Boehringer Ingelheim
- CytoSorbents
- Edwards
- Fresenius Medical Care
- GE Healthcare
- Grifols
- Kyowa Kirin
- Novartis
- NxStage
- Outset
- Potrero
In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据